ClinicalTrials.gg
Active, not recruitingNCT06338267VIBRANTUpdated Aug 31, 2026

Validating Innovative Biosensors for Rett Autonomic Symptom Tracking

An observational study in Rett Syndrome, sponsored by Rett Syndrome Research Trust. Active, not recruiting at 2 sites in United States. Per ClinicalTrials.gov, last updated 2026-08-31.

Sponsored by Rett Syndrome Research Trust · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
30
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 55 studies in Rett Syndrome with a site in United States — 11 open to participants now, 21 under way, 5 of them phase 3. Rett Syndrome · United States.

Planned enrollment
16th of 21
30 · median 146
Started
2025
with 2 others
Observational
21 of 55
6 open now
Primary completion
2026-11
later than 3 of 20 live
Registered
45th of 55
by date
Lead sponsor
5 of 55
Rett Syndrome Research Trust

Among the 55 studies in Rett Syndrome with a site in United States, this one is the 16th largest by planned enrollment of the 21 observational ones that give a count, is one of 3 that started in 2025, is one of 21 observational ones, reaches primary completion later than 3 of the 20 other live ones, and was the 45th registered.

Rett Syndrome

96 studies on the registry are indexed under Rett Syndrome; 19 are open to participants now.

Browse Rett Syndrome studies →

Open to participants now

11 of the 55 studies in Rett Syndrome with a site in United States are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 14 Rett Syndrome studies recruiting now, 4 (29%) set no upper age limit and 7 (50%) stop at 75 or younger; 12 take children under 18; 3 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies in Rett Syndrome with a site in United States, or all of them as a file.
02

Study summary

The VIBRANT study aims to validate biosensors to objectively and directly measure symptoms in Rett syndrome and create confidence in the use of these devices in clinical trials. VIBRANT will use several FDA-cleared wearable biosensors and a non-wearable device to collect symptom data from patients with Rett syndrome for up to 9 weeks. Symptoms of interest include heart rate, breathing, sleep, blood oxygen levels, and movement. Participants will use the biosensors intermittently at home, document device use and symptom status, and will come to the clinic for 1 overnight sleep study. A cohort of up to 10 participants receiving an intervention in a separate clinical trial may also enroll and participate on a custom device schedule for up to 1 year.

The study will provide information on the feasibility and ease of use for families at home, biosensor data will be compared to data collected at the same time from the overnight sleep study to demonstrate how well they work in individuals with Rett syndrome, and Emerald will be developed to include movement as a measurable symptom.

Read the detailed description

Clinical trials in Rett syndrome typically use subjective assessment scales to assess changes in symptoms. These scales require observer interpretation and can be subject to bias and placebo effect. They are often not fit for purpose, are adapted from other disorders, are not properly validated for use in Rett and therefore are not optimal tools to accurately and reliably assess symptom change.

The VIBRANT study aims to validate biosensors to objectively and directly measure symptoms in Rett syndrome and create confidence in these devices for use in clinical trials. VIBRANT will use several biosensors to collect symptom data from patients with Rett syndrome over 9 weeks. The devices under study include the FDA-cleared VV330 ECG patch for heart rate, Kids O2 pulse oximeter ring for blood oxygen levels; and the non-wearable device Emerald for sleep, breathing, and movement.

To be eligible, participants will have an MECP2 genetic variant considered causative for the disorder. Participants will come to the clinic for Screening for an eligibility assessment and will learn to use the biosensors. Participants will use the biosensors on an intermittent schedule at home for between approximately 4 to 9 weeks, depending on the device, and will come to the clinic for 1 overnight sleep study during the 9-week observation period. All devices will be used during the overnight sleep study. The data collected by the biosensors will be compared to the data collected from the overnight sleep study to demonstrate how well they work in individuals with Rett syndrome. A cohort of up to 10 participants receiving an intervention in a separate clinical trial may also enroll and participate on a custom device schedule for up to 1 year.

The goals of the study are to demonstrate FDA-cleared devices to assess heart rate, breathing, and oxygen saturation can be reliably used in Rett individuals, both adult and pediatric; determine how accurate and reliable the biosensor results are compared to the overnight sleep study, or to other FDA-cleared devices at home; to and to develop Emerald's ability to assess movement.

03

Conditions studied

  • Rett Syndrome

Browse trials for

Keywords

  • Rett
  • MECP2
  • RTT
  • device
  • biosensor
  • Emerald
  • Vivalink
  • Kids O2
  • sensor
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Participants must have a documented genetic variant in MECP2 considered causative for Rett syndrome, must be generally healthy, able to tolerate device use.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • diagnosis of Rett syndrome with a causative MECP2 genetic variant
  • Access to WiFi

Exclusion criteria

Exclusion Criteria:

  • Inability of participant to sleep alone
  • prolonged absence from home
  • medication use that may impact heart rate
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
30 participants (estimated)
Patient registry
No

Groups and cohorts

  • Main

    Participants who are not in a separate interventional treatment trial

  • Intervention

    Participants who are also in a separate interventional treatment trial

06

What researchers measure

Primary outcomes

  1. Assess heart rate variability with Vivalink VV330 ECG patch

    Use FDA-cleared Vivalink VV330 patch to directly and objectively measure heart rate parameters

    Time frame: 4 weeks

  2. Assess blood oxygen levels with Viatom Kids O2 pulse oximeter ring

    Use FDA-cleared Viatom Kids O2 pulse oximeter ring to directly and objectively measure blood oxygen levels

    Time frame: 6 weeks

  3. Validate FDA-cleared Vivalink VV330 ECG patch for heart rate variability metrics in Rett syndrome compared to in-lab PSG

    Comparison of results from ECG patch to PSG ECG results to determine accuracy and reliability

    Time frame: During PSG comparison (1 night)

  4. Validate ECG-derived breathing compared to in-lab PSG

    Comparison of results from ECG-derived breathing to PSG breathing results to determine accuracy and reliability

    Time frame: During PSG comparison (1 night)

  5. Validate FDA-cleared Viatom Kids O2 pediatric pulse oximeter ring in Rett syndrome compared to in-lab PSG and/or Nonin wristOx pulse oximeter

    Comparison of results from pulse oximeter ring to PSG pulse oximeter results to determine accuracy and reliability

    Time frame: During PSG comparison (1 night)

  6. Validate Emerald ability to reliably measure breathing and sleep compared to in-lab PSG

    Compare Emerald to directly and objectively measure sleep and night time breathing

    Time frame: During PSG comparison (1 night)

  7. Validate Emerald ability to reliably measure breathing and sleep at home compared to FDA-cleared comparator

    Compare Emerald to FDA-cleared SleepView home sleep test to directly and objectively measure sleep and night time breathing

    Time frame: 9 weeks

  8. Develop Emerald ability to measure daytime movement

    Compare Emerald signals of movement with video

    Time frame: 9 weeks

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2025 (actual). Primary completion is estimated for Nov 2026, 20 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 22, 2024
First posted
Mar 29, 2024
StartActual
Mar 3, 2025
Primary completionEst.
Nov 2026
CompletionEst.
Nov 2026
Last update
Aug 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06338267
Lead sponsor
Rett Syndrome Research Trust
Responsible party
Sponsor
First posted
Mar 29, 2024
Start date
Mar 3, 2025
Primary completion
Nov 2026 (estimated)
Completion
Nov 2026 (estimated)
Last update
Aug 31, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion